These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

356 related items for PubMed ID: 30922043

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D, Hanssens Y, Northway MG.
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Motor features and response to oral levodopa in patients with Parkinson's disease under continuous dopaminergic infusion or deep brain stimulation.
    Elia AE, Dollenz C, Soliveri P, Albanese A.
    Eur J Neurol; 2012 Jan; 19(1):76-83. PubMed ID: 21645174
    [Abstract] [Full Text] [Related]

  • 8. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
    Manson AJ, Turner K, Lees AJ.
    Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062
    [Abstract] [Full Text] [Related]

  • 9. Apomorphine-subcutaneous--Bertek/Britannia.
    Drugs R D; 2004 Nov; 5(4):211-2. PubMed ID: 15230626
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.
    Colzi A, Turner K, Lees AJ.
    J Neurol Neurosurg Psychiatry; 1998 May; 64(5):573-6. PubMed ID: 9598668
    [Abstract] [Full Text] [Related]

  • 16. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
    Katzenschlager R, Hughes A, Evans A, Manson AJ, Hoffman M, Swinn L, Watt H, Bhatia K, Quinn N, Lees AJ.
    Mov Disord; 2005 Feb; 20(2):151-7. PubMed ID: 15390035
    [Abstract] [Full Text] [Related]

  • 17. Apomorphine infusion in advanced Parkinson's patients with subthalamic stimulation contraindications.
    Drapier S, Gillioz AS, Leray E, Péron J, Rouaud T, Marchand A, Vérin M.
    Parkinsonism Relat Disord; 2012 Jan; 18(1):40-4. PubMed ID: 21890396
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.